Scholars Central

Research articlePublished 16 May 2011

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Study background: The objective of this collated research paper is to highlight the anti-diabetic effects and mode of action of imeglimin, the first in a new tetrahydrotriazine-containing class of oral anti-diabetic agents: the glimins. Imeglimin acts on both insulin resistant organs (liver and muscle) and pancreatic β-cells (insulin secretion in response to glucose and protection against apoptosis). Methods: The aim of the investigations reported here is to present data on the mode of action of imeglimin and its anti-diabetic effects, demonstrating that it represents a promising treatment for type 2 diabetes by acting on the three key pathological defects of the disease, namely excessive hepatic glucose production, impaired peripheral glucose uptake by skeletal muscle, and insufficient insulin secretion. Results: Imeglimin significantly lowered fasting plasma glucose concentrations in a dose-dependent manner in STZ rats. HbA1c was significantly reduced (P<0.01) by imeglimin (6.2%) compared with controls (9.83%). At a 150 mg·kg-1 dose, imeglimin significantly improved glucose tolerance compared with controls (AUC0-3h 2,402 vs 3,449 mmol·L·h-1 respectively). With regards to its mode of action, imeglimin significantly decreased the rate of hepatic gluconeogenesis, stimulated muscle glucose uptake, induced a potentiation of glucose-dependent insulin secretion, and decreased β-cell apoptosis. Conclusion: Our investigations found that imeglimin uniquely targets the three key defects of type 2 diabetes. It could provide more durable, sustained glycemic control than currently achieved with oral anti-diabetics and has the potential to be used at any stage in the disease continuum. Imeglimin’s potential for combination with other oral antidiabetics is also under investigation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDentistry & Oral Health
  • SubjectDiabetes & Endocrinology
  • SubjectPharmaceutical Sciences